Table 1.
Overview of datasets used.
Fig 1.
a-b. Schematic representation of the long-term and short-term modeling, respectively.
a) Long-term modeling approach includes the baseline antibody level only and no further readings, b) Short-term modeling approach includes the baseline antibody level
only and no prior readings.
Table 2.
Performance of different models and regression methods on test data. R-squared and RMSE metrics are used.
Fig 2.
a-b: Distribution of errors (residuals) on test set with long-term model and EBM.
a) Long-term model, b) Short-term model.
Table 3.
R-squared in longitudinal performance evaluation of the models with 20% of Pers-007 as test data for different training datasets. Subjects under the test set were excluded from each training set.
Fig 3.
a-k: Sample trajectories of the predicted and true reference rSBA titer levels for different individual subjects.
The vertical lines represent the vaccination times and the stand-alone (diamond-shaped) points represent the initial baseline for the rSBA titer levels. The type of the vaccines given (no vaccine or a placebo was given in some cases, indicated by ‘none’) is mentioned under each subfigure. a) 1st: PsA-TT, 2nd: Hib-TT, b) 1st: PsA-TT, 2nd: 1/5th dose of PsACWY, c) 1st: PsA-TT, 2nd: 1/5th dose of PsACWY, d) 1st: PsA-TT, 2nd: none, 3rd: PsA-TT, e) 1st: none, 2nd: none, 3rd: PsA-TT, f) 1st: none, 2nd: none, 3rd: PsA-TT, g) 1st: none, 2nd: none, 3rd: PsA-TT, h) 1st: PsA-TT, 2nd: Hib-TT, 3rd: PsA-TT, i) 1st: PsA-TT, 2nd: Hib-TT, 3rd: PsA-TT, j) 1st: PsA-TT, 2nd: Hib-TT, 3rd: PsA-TT, k) 1st: PsA-TT, 2nd: Hib-TT, 3rd: PsA-TT.
Fig 4.
a-b: Relative importance (as weights) of top 15 features for long-term and short-term model with EBM.
a) Long-term model, b) Short-term model.
Table 4.
Impact of different vaccine groups on immunity. Groups with less than 100 subjects are excluded.
Fig 5.
Impact of the time* elapsed since first vaccination.
*We should note that certain ranges (78.6–129 and 483–736 days) did not have enough sample to obtain a reliable estimate of the impact, while the drop in immunity around 280 days, 430 days and 800 days were obvious as there are more samples around these timepoints.